Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes.

Leukocyte infiltration and adhesion molecule activation play a central role in the pathogenesis of angiotensin II (Ang II)-induced end-organ damage in double transgenic rats (dTGR) harboring human renin and angiotensinogen genes. We tested the hypothesis that the immunosuppressive agent cyclosporine (CsA) protects against the Ang II-induced myocardial and renal damage in dTGR. Furthermore, we investigated the influence of CsA on interleukin-6 (IL-6) and inducible nitric oxide synthase (iNOS) expression and the DNA binding activity of transcription factor necrosis factor-kappaB (NF-kappaB). The 4-week-old rats were divided into 4 groups: (1) control dTGR (n=20), (2) dTGR plus CsA (5 mg/kg SC for 3 weeks, n=15), (3) normotensive Sprague-Dawley (SD) rats (n=10), and (4) SD rats plus CsA (n=8). In dTGR, CsA completely prevented cardiovascular death (0 of 15 versus 9 of 20), decreased 24-hour albuminuria by 90% and systolic blood pressure by 35 mm Hg, and protected against the development of cardiac hypertrophy. Whole blood CsA concentrations 24 hours after the last drug treatment were 850+/-15 ng/mL. Semiquantitative ED-1 and Ki-67 (a nuclear cell proliferation-associated antigen) scoring showed that CsA prevented perivascular monocyte/macrophage infiltration and prevented cell proliferation in the kidneys and hearts of dTGR, respectively. The beneficial effects of CsA were, at least in part, mediated by the suppression of IL-6 and iNOS expression. Electrophoretic mobility shift assay revealed that CsA regulated inflammatory response in part through the NF-kappaB transcriptional pathway. In contrast to dTGR, CsA increased blood pressure in normotensive SD rats by 10 mm Hg and had no effect on cardiac mass or 24-hour urinary albumin excretion. Perivascular monocyte/macrophage infiltration, IL-6, and iNOS expression or cell proliferation were not affected by CsA in SD rats. Our findings indicate that CsA protects against Ang II-induced end-organ damage and underscore the central role of vascular inflammatory response in the pathogenesis of myocardial and renal damage in dTGR. The beneficial effects of CsA in the kidney and heart are mediated, at least in part, by suppression of IL-6 and iNOS expression via NF-kappaB transcriptional pathway.

[1]  P. Libby,et al.  Angiotensin induces inflammatory activation of human vascular smooth muscle cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[2]  A. Takeshita,et al.  Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. , 1999, Hypertension.

[3]  A. Khanna,et al.  Cyclosporine induces the expression of the cyclin inhibitor p21. , 1999, Transplantation.

[4]  M. Runge,et al.  Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. , 1999, Circulation research.

[5]  T. Borg,et al.  Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. , 1999, Circulation research.

[6]  R. Walsh.  Calcineurin inhibition as therapy for cardiac hypertrophy and heart failure: requiescat in pace? , 1999, Circulation research.

[7]  E. Olson,et al.  Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. , 1999, Circulation research.

[8]  E. Olson,et al.  Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. , 1999, Circulation research.

[9]  E. Olson,et al.  Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype? , 1999, Circulation research.

[10]  P. Sugden,et al.  Signaling in myocardial hypertrophy: life after calcineurin? , 1999, Circulation research.

[11]  G. Crabtree.  Generic Signals and Specific Outcomes Signaling through Ca2+, Calcineurin, and NF-AT , 1999, Cell.

[12]  D. Ganten,et al.  Hypertension-induced end-organ damage : A new transgenic approach to an old problem. , 1999, Hypertension.

[13]  D. Ganten,et al.  Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. , 1999, Hypertension.

[14]  K. Walsh,et al.  Calcineurin inhibitors and cardiac hypertrophy , 1998, Nature Medicine.

[15]  Mark A Sussman,et al.  Prevention of cardiac hypertrophy in mice by calcineurin inhibition. , 1998, Science.

[16]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[17]  L. Lindgren,et al.  Effects of dietary sodium and magnesium on cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. , 1997, Hypertension.

[18]  D. Beasley,et al.  Phorbol ester and interleukin-1 induce interleukin-6 gene expression in vascular smooth muscle cells via independent pathways. , 1997, Journal of cardiovascular pharmacology.

[19]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[20]  J. Ménard,et al.  High human renin hypertension in transgenic rats. , 1997, Hypertension.

[21]  C. Scheidereit,et al.  Different mechanisms control signal‐induced degradation and basal turnover of the NF‐kappaB inhibitor IkappaB alpha in vivo. , 1996, The EMBO journal.

[22]  R. Knuechel,et al.  Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. , 1996, The Journal of clinical investigation.

[23]  E. Imai,et al.  Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. , 1995, Journal of the American Society of Nephrology : JASN.

[24]  A. Rao,et al.  Cyclosporin A sensitivity of the NF-χB site of the IL2Rα promoter in untransformed murine T cells , 1994 .

[25]  D. Faulds,et al.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. , 1993 .

[26]  J. Arnold,et al.  The role of interleukin 6 in megakaryocyte formation, megakaryocyte development and platelet production. , 2007, Ciba Foundation symposium.

[27]  D. Ganten,et al.  Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Akira,et al.  IL‐6 and NF‐IL6 in Acute‐Phase Response and Viral Infection , 1992, Immunological reviews.

[29]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[30]  U. Ikeda,et al.  Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. , 1991, The American journal of physiology.

[31]  P. Libby,et al.  Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. , 1990, The Journal of clinical investigation.

[32]  P. Libby,et al.  Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. , 1989, Cellular immunology.

[33]  T. Hirano,et al.  Synergistic Regulatory Effects of Interleukin 6 and Interleukin 1 on the Growth and Differentiation of Human and Mouse Myeloid Leukemic Cell Lines 1 , 2006 .

[34]  J. Vilček,et al.  Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. , 1989, Laboratory investigation; a journal of technical methods and pathology.